-
Innovation Ranking
NewInnovation Ranking – Swedish Match AB
Swedish Match AB (Swedish Match) is a tobacco manufacturing company that produces and sells cigars and smokeless tobacco products. The company’s product portfolio comprises snuff, snus, cigars, chewing tobacco, pipe tobacco, lighters, matches, and other related products. It sells products under Ettan, Longhorn, Nick and Johnny, The Lab, Goteborgs Rape, Catch, Kronan, Timber Wolf, America’s Best Chew, Kaliber, General, White Owl, Solstickan, Redheads, Nitedals, Garcia y Vega, Thunder, Oliver Twist, and Cricket brands. Swedish Match offers disposable razors, batteries, and...
-
Innovation Ranking
NewInnovation Ranking – Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB (Sobi) is an integrated biopharmaceutical company. It focuses on the development of products for the treatment of a few rare diseases. The company specializes in biotechnology with prime capabilities in protein biochemistry and biologics manufacturing. Its product portfolio focuses on hemophilia, immunology, specialty care, inflammation, and genetic and metabolic diseases. The company also provides innovative treatment for conditions such as amyotrophic lateral sclerosis (ALS). Sobi also manufactures and markets specialty products for rare diseases for partner...
-
Product Insights
NewNet Present Value Model: Swedish Orphan Biovitrum AB’s Zurase
Empower your strategies with our Net Present Value Model: Swedish Orphan Biovitrum AB's Zurase report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Swedish Orphan Biovitrum AB’s Pegadricase
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
NewNet Present Value Model: Swedish Orphan Biovitrum AB’s Efanesoctocog alfa
Empower your strategies with our Net Present Value Model: Swedish Orphan Biovitrum AB's Efanesoctocog alfa report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Insights
Innovation and Patenting activity of Swedish Match AB Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Swedish Match AB Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Company Insights
Innovation and Patenting activity of Swedish Orphan Biovitrum AB Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Swedish Orphan Biovitrum AB Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Company Insights
NewSwish – Competitor Profile
Swish is a Swedish mobile payment solution launched in 2012. It is one of the leading P2P payment solutions in Europe, with 8.4 million users. Initially launched as a P2P payment service, it was extended to allow merchants to accept payments for online and offline purchases. The solution enables users to make real-time P2P transfers from their smartphone using the recipient’s phone number or QR code. To transfer funds, both sender and recipient need to have a bank account with...
-
Product Insights
NewNet Present Value Model: Eli Lilly and Co’s LY-3556050
Empower your strategies with our Net Present Value Model: Eli Lilly and Co's LY-3556050 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VG-201 in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VG-201 in Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VG-201 in Pancreatic Cancer Drug Details: VG-201 is under development for...